OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Reviews is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	133
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	128
Editorial Board	128
Clinical burden of hemophilia in older adults: Beyond bleeding risk	87
Artificial intelligence in sickle disease	59
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	59
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	55
The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload	53
Radiation and leukaemia: Which leukaemias and what doses?	49
Thalassaemia in China	48
Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders	46
Not all LGL leukemias are created equal	45
Advances in the critical care management for patients with hematological malignancies	44
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	41
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	41
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	41
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	40
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	39
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	38
Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemia	38
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	36
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	35
Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia	35
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	35
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	34

The acute pain crisis in sickle cell disease: What can be done to improve outcomes?	33
Chasing leukemia differentiation through induction therapy, relapse and transplantation	33
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	33
Immune thrombocytopenia: A review of upfront treatment strategies	32
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	32
CHIPing away the progression potential of CHIP: A new reality in the making	31
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	31
Endothelial cells: major players in acute myeloid leukaemia	31